Evaluation of Depression and Anxiety Disorders and Correlation with the Treatment of Patients with Psoriasis Vulgaris

Introduction: Psoriasis is a chronic inflammatory multisystemic disease with several comorbidities, namely anxiety and depression disorders. Methods: In this study, the prevalence of these psychiatric entities was investigated by the PHQ-9 and GAD-7 questionnaries and related to the socio-demographic variables and to the forms of clinical treatment. Results: A total of 90 patients (56 females) were analyzed. Of these, 41 patients (45.56%) used topical treatment only, 28 patients (31.11%) used oral methotrexate and 21 patients (23.33%) used immunobiological agents (anti-TNF-alfa agents). It was observed that 47 patients (52.23%) presented some degree of depression (mild, moderate or severe) and 53 patients (58.89%) presented some degree of anxiety disorder (mild, moderate or severe). There was no statistical relationship between the anxiety and depression scores and the PASI score, as well as age, employability or schooling. There was a statistical association between psychiatric comorbidities and the female gender (p <0.0001). It was also observed a lower prevalence of depression (p = 0.0336) on patients using immunobiological treatments. Conclusion: The findings confirm published data, showing association of psychiatric conditions with psoriasis, especially in relation to TNF-alpha, so that anti-TNF therapies may become an alternative for the treatment of depression or anxiety disorders associated with psoriasis.

Download Full-text

Prevalence of anxiety and depression among domestic and foreign medical students in Poland

Polish Annals of Medicine ◽

10.29089/2020.20.00125 ◽

2020 ◽

Author(s):

Aneta Anna Jaroszewska ◽

Szymon Tyras ◽

Martyna Dziewit ◽

Joanna Jaroszewska ◽

Katarzyna Podhorodecka

Keyword(s):

Medical Student ◽

Medical Students ◽

Anxiety Disorders ◽

Study Groups ◽

Anxiety And Depression ◽

Depression And Anxiety ◽

Student Group ◽

Significant Difference ◽

Prevalence Of Depression ◽

Depression Disorders

Introduction: Depression and anxiety disorders are much more common among medical students than in the general population. Due to additional risk factors, foreign students may be particularly vulnerable. Despite this, there is still an insufficient number of studies analyzing the prevalence of mental disorders among foreign medical students, especially in Poland. Aim: The aim of the study was to assess and compare the prevalence of anxiety and depression disorders between domestic and foreign medical students in Poland. Material and methods: An anonymous internet survey containing questions about socio-demography and the Hospital Anxiety and Depression Scale questionnaire was distributed among students. Based on the field of study and country of origin, participants were divided into 3 groups – Polish medical student group (PMG, n = 214); foreign medical student group (FMG, n = 59) and control group, which were Polish students of other faculties (CG, n = 476). The study groups were compared using the χ2 test. Results and discussion: The prevalence of depression disorders was 30%, 31% and 28% (PMG, FMG and CG, respectively). No statistically significant difference was observed between the study groups (P = 0.77). The prevalence of anxiety disorders was 57%, 90% and 59% (PMG, FMG and CG, respectively). Anxiety disorders were more common among FMG as compared to PMG and CG (P < 0.01 in both cases). Conclusions: The prevalence of depression and anxiety among medical students in Poland is high. Foreign medical students appear to be particularly vulnerable to anxiety disorders.

Download Full-text

Neuropsychiatric Properties of the ACE2/Ang-(1-7)/Mas Pathway: A Brief Review

Protein and Peptide Letters ◽

10.2174/0929866527666191223143230 ◽

2020 ◽

Vol 27 (6) ◽

pp. 476-483 ◽

Cited By ~ 1

Author(s):

Leonardo Augusto de Melo ◽

Ana Flávia Almeida-Santos

Keyword(s):

Anxiety Disorders ◽

Therapeutic Target ◽

Clinical Success ◽

Renin Angiotensin System ◽

Anxiety And Depression ◽

Time Range ◽

Proven Efficacy ◽

Pubmed Search ◽

Depression Disorders ◽

New Research

The current pharmacological strategies for the management of anxiety disorders and depression, serious conditions which are gaining greater prevalence worldwide, depend on only two therapeutic classes of mood-stabilizing drugs: Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs). Although first line agents with proven efficacy, their clinical success in the management of anxiety disorders and depression is still considered highly complex due to the multifaceted nature of such conditions. Several studies have shown a possible therapeutic target could be found in the form of the Angiotensin-Converting Enzyme [ACE] type 2 (ACE2), Angiotensin [Ang]-(1-7) and Mas receptor pathway of the Renin- Angiotensin System (RAS), which as will be discussed, has been described to exhibit promising therapeutic properties for the management of anxiety disorders and depression. In this article, the literature to describe recent findings related to the role of the RAS in anxiety and depression disorders was briefly revised. The literature used covers a time range from 1988 to 2019 and were acquired from the National Center for Biotechnology Information’s (NCBI) PubMed search engine. The results demonstrated in this review are promising and encourage the development of new research for the treatment of anxiety and depression disorders focusing on the RAS. In conclusion, the ACE2/Ang-(1-7)/Mas pathway may exhibit anxiolytic and anti-depressive effects through many possible biochemical mechanisms both centrally and peripherally, and result in highly promising mental health benefits which justifies further investigation into this system as a possible new therapeutic target in the management of neuropsychiatric disorders, including any as of yet undescribed risk-benefit analysis compared to currently-implemented pharmacological strategies.

Download Full-text

Depressive Psoriasis-Patienten können ein schlechteres Ansprechen auf Etanercept zeigen

Karger Kompass Dermatologie ◽

10.1159/000496272 ◽

2019 ◽

Vol 7 (2) ◽

pp. 75-76

Author(s):

Wiebke Sondermann

Keyword(s):

Clinical Response ◽

Response Rate ◽

Depression Scale ◽

Female Gender ◽

Anxiety Symptoms ◽

Anxiety And Depression ◽

Depression Symptoms ◽

Etanercept Treatment ◽

Depressed Patients ◽

Pasi Score

Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 psoriasis patients who received 6 months of etanercept treatment were consecutively enrolled in this prospective cohort study. The Psoriasis Area and Severity Index (PASI) score was evaluated at month 0 (M0), M1, M3, and M6, and the corresponding PASI 75/90 response at each visit was assessed. Also, anxiety and depression symptoms were assessed by the Hospital Anxiety and Depression Scale (HADS) at M0, M1, M3, and M6. Results: Depression symptoms were observed to correlate with female gender (p = 0.004), longer disease duration (p = 0.018), and higher PASI score (p < 0.001), and anxiety symptoms were seen to be associated with female gender (p = 0.017), larger psoriasis-affected body surface area (p = 0.049), and higher PASI score (p = 0.017) in psoriasis patients. After etanercept treatment, HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores were both decreased at M1, M3, and M6 (all p < 0.001) compared with M0. Most importantly, baseline depressed patients presented with a lower PASI 75 response rate at M3 (p = 0.014) and M6 (p = 0.005), and a reduced PASI 90 response rate at M6 (p = 0.045) compared with baseline non-depressed patients. Furthermore, multivariate logistic regression analyses revealed that depression symptoms at baseline were an independent predictive factor for the lower possibility of both PASI 75 response (p = 0.048) and PASI 90 response (p = 0.048) achievements at M6 in psoriasis patients. However, no correlation of baseline anxiety symptoms with PASI 75/90 responses was observed. Conclusion: Depression symptoms at baseline independently predict a worse clinical response to etanercept treatment in psoriasis patients.

Download Full-text

Recognizing the Psychiatric Burden of Anxiety and Depression in Children With Headache, Chest Pain, and Abdominal Pain

Overlapping Pain and Psychiatric Syndromes ◽

10.1093/med/9780190248253.003.0012 ◽

2020 ◽

pp. 160-175

Author(s):

Susan T. Tran ◽

Ana B. Goya Arce ◽

Anjana Jagpal

Keyword(s):

Chronic Pain ◽

Functional Disability ◽

Anxiety And Depression ◽

Depression And Anxiety ◽

Pediatric Pain ◽

Treatment Of Depression ◽

Pediatric Chest ◽

Psychiatric Conditions ◽

Headache Pain

Anxiety and depression are particularly common in pediatric chest, abdominal, and headache pain. Shared genetic factors, biological processes, and neurochemical mechanisms may underlie these comorbidities. Chronic pain in children and adolescents is associated with substantial functional disability, and impairments are especially notable when youths have comorbid anxiety or depression. Thus, early detection and treatment of comorbid psychiatric conditions in youths with chronic pain is imperative. Screening for anxiety and depression in pediatric pain is made difficult by the number of overlapping symptoms between pain and psychiatric conditions. Research on the treatment of chronic pain and comorbid depression or anxiety has advanced, but larger trials with follow-up data are needed to improve confidence in effectiveness. Implications for considering developmental and familial factors in the screening and treatment of depression and anxiety in youths with chronic pain are discussed.

Download Full-text

AB0123 ANXIETY AND DEPRESSION DURING RHEUMATOID ARTHRITIS

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.2066 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 1090.3-1091

Author(s):

L. Ben Ammar ◽

S. Rekik ◽

S. Boussaid ◽

S. Jemmali ◽

E. Cheour ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Anxiety Disorders ◽

Rural Areas ◽

Insurance Coverage ◽

Depression Scale ◽

Health Insurance Coverage ◽

Anxiety And Depression ◽

Cross Sectional ◽

Delay In Diagnosis ◽

Depression Disorders

Background:Although the management of rheumatoid arthritis (RA) has been booming since the advent of biological treatments, the consequences of this disease remain multiple, both physical and psychological.Objectives:The aim of our work was to investigate the factors influencing anxiety and depression in RA.Methods:This was a cross-sectional study of 49 RA patients. We used the Hospital Anxiety and Depression scale (HAD) to assess anxiety disorders.Results:We included 24 women and 5 men with an average age of 54.1 years. Sixty-nine percent of patients were unemployed and 81% had health insurance coverage. RA had been evolving for an average of 11.43 ± 7.32 years and the mean time to diagnosis was 2.35 years. It was erosive in 93.8% of cases. An atlanto-axial dislocation was found in 4.1% of cases and coxitis in 8.2% of cases. Eighty-three percent of patients were on cs-DMARDs and 14.2% were on biotherapy. Most patients had low active disease (53%) with a mean DAS28CRP score of 2.74 ± 0.81. Twelve percent of patients had a probable anxiety and 18% had a probable depression.A long delay in diagnosis was associated with a higher risk of anxiety disorders. Working patients had a lower risk of depression while patients from rural areas had a higher risk. The risk of anxiety and depression disorders was associated with increased VAS pain, EGP, and DAS28. In the multivariate study, EGP was the independent risk factor for the development of anxiety and depression disorders.Conclusion:Anxiety and depression disorders are a frequent yet underestimated consequence in RA. Appropriate care in psychiatry is required as soon as the diagnosis is announced.Disclosure of Interests:None declared

Download Full-text

Depressive Psoriasis-Patienten können ein schlechteres Ansprechen auf Etanercept zeigen - eine weitere Expertenmeinung

Karger Kompass Dermatologie ◽

10.1159/000496947 ◽

2019 ◽

Vol 7 (2) ◽

pp. 77-79

Author(s):

Uwe Gieler

Keyword(s):

Clinical Response ◽

Response Rate ◽

Depression Scale ◽

Female Gender ◽

Anxiety Symptoms ◽

Anxiety And Depression ◽

Depression Symptoms ◽

Etanercept Treatment ◽

Depressed Patients ◽

Pasi Score

Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 psoriasis patients who received 6 months of etanercept treatment were consecutively enrolled in this prospective cohort study. The Psoriasis Area and Severity Index (PASI) score was evaluated at month 0 (M0), M1, M3, and M6, and the corresponding PASI 75/90 response at each visit was assessed. Also, anxiety and depression symptoms were assessed by the Hospital Anxiety and Depression Scale (HADS) at M0, M1, M3, and M6. Results: Depression symptoms were observed to correlate with female gender (p = 0.004), longer disease duration (p = 0.018), and higher PASI score (p < 0.001), and anxiety symptoms were seen to be associated with female gender (p = 0.017), larger psoriasis-affected body surface area (p = 0.049), and higher PASI score (p = 0.017) in psoriasis patients. After etanercept treatment, HADS-Depression (HADS-D) and HADSAnxiety (HADS-A) scores were both decreased at M1, M3, and M6 (all p < 0.001) compared with M0. Most importantly, baseline depressed patients presented with a lower PASI 75 response rate at M3 (p = 0.014) and M6 (p = 0.005), and a reduced PASI 90 response rate at M6 (p = 0.045) compared with baseline non-depressed patients. Furthermore, multivariate logistic regression analyses revealed that depression symptoms at baseline were an independent predictive factor for the lower possibility of both PASI 75 response (p = 0.048) and PASI 90 response (p = 0.048) achievements at M6 in psoriasis patients. However, no correlation of baseline anxiety symptoms with PASI 75/90 responses was observed. Conclusion: Depression symptoms at baseline independently predict a worse clinical response to etanercept treatment in psoriasis patients.

Download Full-text

Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients

Dermatology ◽

10.1159/000492784 ◽

2018 ◽

Vol 235 (1) ◽

pp. 55-64 ◽

Cited By ~ 3

Author(s):

Waishu Jin ◽

Shuqing Zhang ◽

Yanjuan Duan

Keyword(s):

Clinical Response ◽

Response Rate ◽

Depression Scale ◽

Female Gender ◽

Anxiety Symptoms ◽

Anxiety And Depression ◽

Depression Symptoms ◽

Etanercept Treatment ◽

Depressed Patients ◽

Pasi Score

Download Full-text

Psychodinamic Aspect in Mixed Anxiety and Depression Disorder: a Case Report

Scientia Psychiatrica ◽

10.37275/scipsy.v1i4.24 ◽

2020 ◽

Vol 1 (4) ◽

pp. 24-28

Author(s):

Lisda Yanti ◽

Mahar Agusno

Keyword(s):

Case Report ◽

Anxiety Disorders ◽

Depressed Mood ◽

Anxiety And Depression ◽

Thin Body ◽

Psychiatric Clinic ◽

Case Presentation ◽

Icd 10 ◽

Depression Disorders ◽

Depression Disorder

Abstract Introduction. According to the ICD-10 criteria, mixed anxiety disorders and depression (MADD) are characterized by symptoms of anxiety and subsyndromal depression that occur together, but nothing dominates. A mixture of anxiety and depression disorders have various risk factors that underlie the occurrences. This case report aims to discuss the mixture of anxiety and depression disorders and their background. Case Presentation. A man, 23 years old, college student, single, middle down the socio-economic background, lived in a rural area in Yogyakarta, came to consult a psychiatrist at the psychiatric clinic Dr. Sardjito general hospital with complaints felt excessive anxiety and depressed because they were unable to do the thesis. From the psychiatric examination, it was found that men according to age, good self-care, thin body posture, many bowed, often moving his hands, looking nervous, cooperative, intonation and small voice volume, clear articulation, depressed mood, depressed mood, inappropriate affect, realistic thought, worried, worried about moving house, worried about the future, worried about people's assumptions about patients for fear of being blamed, sinful ideas, low self-esteem ideas, ideas of reference, ambivalence, a progression of coherent thought, relevance, good orientation, good memory, mental relations can, there are disturbances in concentration and attention, good impulse control. The patient realizes that what he is thinking is not real and only exists in his mind. Conclusion. Psychodynamic aspects have a role in anxiety disorders and depression.

Download Full-text

Effects of an Anxiety-Specific Psychometric Factor on Fear Conditioning and Fear Generalization

Zeitschrift für Psychologie ◽

10.1027/2151-2604/a000304 ◽

2017 ◽

Vol 225 (3) ◽

pp. 200-213 ◽

Cited By ~ 1

Author(s):

Christian Baumann ◽

Miriam A. Schiele ◽

Martin J. Herrmann ◽

Tina B. Lonsdorf ◽

Peter Zwanzger ◽

...

Keyword(s):

Risk Factor ◽

Anxiety Disorders ◽

Fear Conditioning ◽

Longitudinal Design ◽

Principal Component ◽

Anxiety And Depression ◽

Specific Factor ◽

High Anxious ◽

Two Factors ◽

Fear Generalization

Abstract. Conditioning and generalization of fear are assumed to play central roles in the pathogenesis of anxiety disorders. Here we investigate the influence of a psychometric anxiety-specific factor on these two processes, thus try to identify a potential risk factor for the development of anxiety disorders. To this end, 126 healthy participants were examined with questionnaires assessing symptoms of anxiety and depression and with a fear conditioning and generalization paradigm. A principal component analysis of the questionnaire data identified two factors representing the constructs anxiety and depression. Variations in fear conditioning and fear generalization were solely associated with the anxiety factor characterized by anxiety sensitivity and agoraphobic cognitions; high-anxious individuals exhibited stronger fear responses (arousal) during conditioning and stronger generalization effects for valence and UCS-expectancy ratings. Thus, the revealed psychometric factor “anxiety” was associated with enhanced fear generalization, an assumed risk factor for anxiety disorders. These results ask for replication with a longitudinal design allowing to examine their predictive validity.

Download Full-text

Sex Differences in Anxiety Disorders

The Oxford Handbook of Evolutionary Psychology and Behavioral Endocrinology ◽

10.1093/oxfordhb/9780190649739.013.21 ◽

2019 ◽

pp. 404-432

Author(s):

Teresa A. Piggott ◽

Alexandra N. Duran ◽

Isha Jalnapurkar ◽

Tyler Kimm ◽

Stephanie Linscheid ◽

...

Keyword(s):

Sex Differences ◽

Anxiety Disorder ◽

Anxiety Disorders ◽

Stress Disorder ◽

Obsessive Compulsive ◽

Compulsive Disorder ◽

Considerable Research ◽

Psychosocial Influences ◽

Psychiatric Conditions ◽

The Impact

Women are more likely than men to meet lifetime criteria for an anxiety disorder. Moreover, anxiety is a risk factor for the development of other psychiatric conditions, including major depression. Numerous studies have identified evidence of sex differences in anxiety disorders, and there is considerable research concerning factors that may contribute to vulnerability for anxiety in females. In addition to psychosocial influences, biological components such as the female reproductive hormone cycle have also been implicated. Although psychotropic medication is more likely to be prescribed to women, there is little controlled data available concerning sex differences in the efficacy and/or tolerability of pharmacotherapy in anxiety disorders. This chapter provides an overview of the impact of gender in the epidemiology, phenomenology, course, and treatment response in generalized anxiety disorder (GAD), social anxiety disorder (SAD), posttraumatic stress disorder (PTSD), panic disorder (PD), and obsessive-compulsive disorder (OCD).

Download Full-text